Self-Injectable Belimumab Market Size is Set to Reach USD 7.2 Million by 2024

New York, USA, 2018-Dec-07 — /EPR Network/ —  The European Commission has approved a brand new intravenous formulation of belimumab (Benlysta, GlaxoSmithKline) as an adjunctive treatment for adults with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high grade of disease activity in spite of standard therapy. Further approval in different regions will boost the growth of self-injectable belimumab market.

Self-Injectable Belimumab Market outlook also includes product development, technological advancements, strategic alliances and investment strategies adopted by major market players in order to expand their business across the globe. Moreover, the growing prevalence of systemic lupus erythematosus (SLE) will propel the adoption of self-injectable belimumab in the coming years.

Browse Full Report:

Market Segmentation

On the basis of our in-depth analysis, global Self-Injectable Belimumab market can be segmented as follows:

By Mode of Injection

  • Subcutaneous Autoinjector
  • Subcutaneous Prefilled Syringe
  • Intravenous Infusion

Based on Geography

  • North America (U.S. & Canada) Self-Injectable Belimumab Market
  • Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Self-Injectable Belimumab Market
  • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden &RoE) Self-Injectable Belimumab Market
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Self-Injectable Belimumab Market
  • Middle East & Africa (GCC, South Africa, North Africa, Rome) Self-Injectable Belimumab Market

“Self-Injectable Belimumab Market Report” contains a detailed overview of the global self-injectable belimumab market. On the basis of our in-depth analysis, the market can be segmented in terms of market segmentation by mode of injection.

Download Exclusive Sample Report:

Further, for the in-depth analysis, Global Self-Injectable Belimumab Market Report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis. This market report also includes competitive outlook of some of the major players profiling of companies such as GlaxoSmithKline (GSK).

The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.

Overall, the report represents the global self-injectable belimumab market trends along with the market forecast that will help industry consultants, technology providers, existing players searching for expansion opportunities, new players examining possibilities and other stakeholders to bring into line their market-centric approaches according to the ongoing and expected trends in the future.

Key queries countered in this global self-injectable belimumab market report

  • What is the global self-injectable belimumab market size by 2024 and what would be the expected growth rate of sales?
  • What are the self-injectable belimumab market trends?
  • What are the dynamics which are driving this market?
  • What are the major barriers to self-injectable belimumab market growth?
  • Who are the prominent vendors in this market space?
  • What are the market prospects for the current and entry-level players?
  • What are the latest improvements and market strategies of the key players?

Self-Injectable Belimumab Market is driving on the basis of advancement in mention below industries

Injectable Drugs Market

Injectable Drugs Market is anticipated to reach USD 513.5 billion by 2024 from value USD 272.7 billion in 2016, growing at a CAGR of 8.23% during the forecast period of 2016 to 2024. North America is the dominating region in global injectable drugs market in 2016. Rising number of chronic health issues and increasing number of partnership between medical companies to provide high quality affordable drugs is boosting the demand of injectable drugs in U.S. and Canada. North America valued 109.1 billion in 2016 and is expected to reach USD 184.9 billion by 2024.

Pediatric Vaccines Market

Pediatric Vaccines Market is expected to reach USD 45,600 million by 2025, growing at a CAGR of 10.2% over the forecast period 2017-2025. Pediatric vaccines are one of the most revolutionary invention in medical history which has led to most successful and cost-effective tools for the improvement of public health by preventing the population from the impact of most of the death-causing diseases. The continuous technological growth in the vaccine market such as synthetic vaccinology and platform manufacturing has accelerated the manufacturing process and reduced the time taken new vaccines.


Matched content

Editor’s pick